Dudediligence.

Halozyme Therapeutics, Inc

HALONASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$290.1MSep ’24$298.0MDec ’24$264.9MMar ’25$325.7MJun ’25$354.3MSep ’25$451.8MDec ’25$376.7MMar ’26$481.0MJun ’26
Net income, by quarter
$137.0MSep ’24$137.0MDec ’24$118.1MMar ’25$165.2MJun ’25$175.2MSep ’25−$141.6MDec ’25$150.0MMar ’26$229.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$443.3M$660.1M$829.3M$1.02B$1.40B
Gross profit$361.9M$520.8M$636.9M$855.9M$1.17B
Operating income$275.9M$267.5M$337.6M$551.5M$469.0M
Net income$402.7M$202.1M$281.6M$444.1M$316.9M
Operating cash flow$299.4M$240.1M$388.6M$479.1M$651.6M
Free cash flow$298.0M$235.3M$373.3M$468.4M$644.6M
Cash$118.7M$234.2M$118.4M$115.8M$133.8M
Debt$876.7M$1.51B$1.50B$1.51B$2.14B
Shares outstanding137.5M135.2M126.8M123.1M117.8M